Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
Thursday, May 15, 2025PharmaTher Holdings Ltd a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs today announced the launch of KetaVault
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
Thursday, May 15, 2025Silo Pharma Inca developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems today announced that it has engaged Veloxity Labs LLC for bioanalysis supporting the ongoing investigational
FAMAR Group announces acquisition of sterile manufacturing site in Homburg, Germany
Thursday, May 15, 2025FAMAR Group a leading European pharmaceutical CDMO is pleased to announce the signature of an agreement to acquire a sterile production site in Homburg Germany from MiP Pharma
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
Wednesday, May 14, 2025BioCryst Pharmaceuticals Inctoday announced that the US Food and Drug Administration FDA has accepted its New Drug Application NDA for the use of oral oncedaily ORLADEYO berotralstat in pediatric patients
Synthego Introduces GMP SpCas9 to Accelerate Gene Editing for Therapeutic Advancement
Tuesday, May 13, 2025Synthego has expanded its CRISPR solutions portfolio with the launch of GMP SpCas offering researchers a powerful solution to enhance CRISPRbased therapeutic development The launch of GMP SpCas enables researchers to bundle the nuclease with INDenabl...
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Tuesday, May 13, 2025Moleculin Biotech Inc a latestage pharmaceutical company with a broad portfolio of drug candidates targeting hardtotreat cancers and viral infections today announced that the European Medicines Agency EMA has approved its Clinical Trial Application
Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential
Monday, May 12, 2025AstraZenecas Trixeo Aerosphere already licensed for the treatment of chronic obstructive pulmonary disease COPD in adults has now been approved for use in the UK with an innovative nextgeneration propellant with nearzero
Zealand Pharma announces closing of collaboration and license agreement with Roche
Friday, May 09, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announces that all closing conditions in the collaboration and license agreement with Roche announced on March
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale
Friday, May 09, 2025Peptone a biotech company developing novel therapeutics targeting intrinsically disordered proteins IDPs to treat diseases today announced a partnership with Evotec to accelerate and scale the creation of small molecule IDPtargeted treatments across
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Thursday, May 08, 2025UroGen a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the US Food and Drug Administration FDA has scheduled an Oncologic Drugs Advisory
